Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease.

Incorporating blood-based Alzheimer’s disease biomarkers such as tau and amyloid beta (Aβ) into screening algorithms may improve screening efficiency.